The effect of dietary supplementation of β-carotene on lipid metabolism in streptozotocin-induced diabetic rats

2004 ◽  
Vol 24 (12) ◽  
pp. 1011-1021 ◽  
Author(s):  
Jung Sook Seo ◽  
Kyeung Soon Lee ◽  
Jung Hyun Jang ◽  
Zhejiu Quan ◽  
Kyung Mi Yang ◽  
...  
2020 ◽  
Vol 7 ◽  
Author(s):  
Xupeng Yuan ◽  
Jiahao Yan ◽  
Ruizhi Hu ◽  
Yanli Li ◽  
Ying Wang ◽  
...  

Recent evidences suggest that gut microbiota plays an important role in regulating physiological and metabolic activities of pregnant sows, and β-carotene has a potentially positive effect on reproduction, but the impact of β-carotene on gut microbiota in pregnant sows remains unknown. This study aimed to explore the effect and mechanisms of β-carotene on the reproductive performance of sows from the aspect of gut microbiota. A total of 48 hybrid pregnant sows (Landrace × Yorkshire) with similar parity were randomly allocated into three groups (n = 16) and fed with a basal diet or a diet containing 30 or 90 mg/kg of β-carotene from day 90 of gestation until parturition. Dietary supplementation of 30 or 90 mg/kg β-carotene increased the number of live birth to 11.82 ± 1.54 and 12.29 ± 2.09, respectively, while the control group was 11.00 ± 1.41 (P = 0.201). Moreover, β-carotene increased significantly the serum nitric oxide (NO) level and glutathione peroxidase (GSH-Px) activity (P < 0.05). Characterization of fecal microbiota revealed that 90 mg/kg β-carotene increased the diversity of the gut flora (P < 0.05). In particular, β-carotene decreased the relative abundance of Firmicutes including Lachnospiraceae AC2044 group, Lachnospiraceae NK4B4 group and Ruminococcaceae UCG-008, but enriched Proteobacteria including Bilophila and Sutterella, and Actinobacteria including Corynebacterium and Corynebacterium 1 which are related to NO synthesis. These data demonstrated that dietary supplementation of β-carotene may increase antioxidant enzyme activity and NO, an important vasodilator to promote the neonatal blood circulation, through regulating gut microbiota in sows.


2020 ◽  
Vol 23 (2) ◽  
pp. 87-95
Author(s):  
Pulye Roy ◽  
Monirul Islam ◽  
Mohammad Saiful Islam ◽  
Mamunur Rashid

Diabetes mellitus (DM), characterized by chronic hyperglycemia is one of the most common chronic diseases affecting millions of people worldwide. A significant component of the risk associated with DM is thought to be because of its abnormal lipid ‘triad’ profile. All the associated complications are mainly due to imbalance between generation of free radicals and the antioxidant systems like catalase (CAT) and super oxide dismutase (SOD) enzymes. Moreover, increased level of serum glutamate pyruvate transaminase (SGPT) and serum glutamate oxaloacetate transaminase (SGOT) are considered a consequence of hepatocyte damage. The current study was designed to investigate the antihyperglycemic and antidyslipidemic effects, oxidative stress and liver dysfunction indices of fixed dose combination therapy of sitagliptin [50 mg/70kg body weight (BW)] and β-carotene (5 mg/70kg BW) on streptozotocin (45 mg/kg BW) induced diabetic rats (SIDRs). The study showed that combination therapy induced a significant decrease in blood glucose level (BGL) from 19.09 ± 0.13 to 6.86 ± 0.11 mmol/l in comparison to the control group after daily treatment for three weeks. In case of dyslipidimic effect, combination therapy reduced total cholesterol (TC) (22.96%), triglycerides (TG) (17.54%) and low-density lipoprotein (LDL)-cholesterol (52.25%) levels significantly and increased high-density lipoprotein (HDL)-cholesterol level (55.98%) in comparison with respective diabetic control groups. We also observed that combination therapy lowered SGPT & SGOT level by 46.39% and 37.23%, respectively and increased SOD & CAT enzyme activity by 63.79% and 48.32%, respectively in comparison with diabetic control groups. These changes were significantly better than those of sitagliptin and β-carotene monotherapy. The suggestions of our findings of this research are that combination therapy is more potent than their individual monotherapy and may be beneficial for the treatment of diabetic patients with associated complications. Bangladesh Pharmaceutical Journal 23(2): 87-95, 2020


Author(s):  
Amal J. Fatani ◽  
Salim S. Al-Rejaie ◽  
Hatem M. Abuohashish ◽  
Abdullah Al-Assaf ◽  
Mihir Y. Parmar ◽  
...  

1996 ◽  
Vol 270 (2) ◽  
pp. E344-E352 ◽  
Author(s):  
A. T. Ozcelikay ◽  
D. J. Becker ◽  
L. N. Ongemba ◽  
A. M. Pottier ◽  
J. C. Henquin ◽  
...  

Molybdenum mimics certain insulin actions in vitro. We have investigated the effects of oral administration of Na2MoO4 (Mo) for 8 wk on carbohydrate and lipid metabolism in streptozotocin-diabetic rats. Mo decreased hyperglycemia and glucosuria by 75% and corrected the elevation of plasma nonesterified fatty acids. Tolerance to glucose loads was improved, and glycogen stores were replenished. These effects were not due to a rise of insulinemia. In liver, Mo restored the blunted mRNA and activity of glucokinase and pyruvate kinase and decreased to normal phosphoenolpyruvate carboxykinase values. Finally, Mo totally reversed the low expression and activity of acetyl-CoA carboxylase and fatty acid synthase in liver, but not in white adipose tissue. In conclusion, Mo exerts a marked blood glucose-lowering effect in diabetic rats by an insulin-like action. This effect results in part from a restoration of hepatic glucose metabolism and is associated with a tissue-specific correction of lipogenic enzyme gene expression, both processes being essentially mediated by reversal of impaired pretranslational regulatory mechanisms. These observations raise new therapeutic perspectives in diabetes, particularly in the insulin-resistant condition.


Sign in / Sign up

Export Citation Format

Share Document